Jamie C. DeWitt, Dori R. Germolec, Robert W. Luebke, Victor J. Johnson
{"title":"Associating Changes in the Immune System with Clinical Diseases for Interpretation in Risk Assessment","authors":"Jamie C. DeWitt, Dori R. Germolec, Robert W. Luebke, Victor J. Johnson","doi":"10.1002/0471140856.tx1801s67","DOIUrl":null,"url":null,"abstract":"This overview is an update of the unit originally published in 2004. While the basic tenets of immunotoxicity have not changed in the past 10 years, several publications have explored the application of immunotoxicological data to the risk assessment process. Therefore, the goal of this unit is still to highlight relationships between xenobiotic‐induced immunosuppression and risk of clinical diseases progression. In immunotoxicology, this may require development of models to equate moderate changes in markers of immune functions to potential changes in incidence or severity of infectious diseases. For most xenobiotics, exposure levels and disease incidence data are rarely available, and safe exposure levels must be estimated based on observations from experimental models or human biomarker studies. Thus, it is important to establish a scientifically sound framework that allows accurate and quantitative interpretation of experimental or biomarker data in the risk assessment process. © 2016 by John Wiley & Sons, Inc.","PeriodicalId":72743,"journal":{"name":"Current protocols in toxicology","volume":"67 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/0471140856.tx1801s67","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current protocols in toxicology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/0471140856.tx1801s67","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14
Abstract
This overview is an update of the unit originally published in 2004. While the basic tenets of immunotoxicity have not changed in the past 10 years, several publications have explored the application of immunotoxicological data to the risk assessment process. Therefore, the goal of this unit is still to highlight relationships between xenobiotic‐induced immunosuppression and risk of clinical diseases progression. In immunotoxicology, this may require development of models to equate moderate changes in markers of immune functions to potential changes in incidence or severity of infectious diseases. For most xenobiotics, exposure levels and disease incidence data are rarely available, and safe exposure levels must be estimated based on observations from experimental models or human biomarker studies. Thus, it is important to establish a scientifically sound framework that allows accurate and quantitative interpretation of experimental or biomarker data in the risk assessment process. © 2016 by John Wiley & Sons, Inc.
免疫系统变化与临床疾病在风险评估中的关联解释
本概述是2004年最初发布的单元的更新。虽然免疫毒性的基本原则在过去10年没有改变,但一些出版物已经探讨了免疫毒理学数据在风险评估过程中的应用。因此,本单元的目标仍然是强调异种生物诱导的免疫抑制与临床疾病进展风险之间的关系。在免疫毒理学中,这可能需要建立模型,将免疫功能标记物的适度变化与传染病发病率或严重程度的潜在变化等同起来。对于大多数外源性药物,很少有接触水平和疾病发生率的数据,必须根据实验模型或人类生物标志物研究的观察结果估计安全接触水平。因此,重要的是建立一个科学合理的框架,以便在风险评估过程中对实验或生物标志物数据进行准确和定量的解释。©2016 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。